Young Blood

Recently researchers and ambitious start-ups have promoted the idea that young blood may be used to reverse the aging process. This idea has roots going back thousands of years of human history. A company is offering $8000 for an infusion of plasma from a young donor. But the FDA pushed back with a warning that there is little evidence to support the companies claim: (

But what could be learned from the study of young blood versus ‘old blood’? Perhaps identifying differences in circulating stem cells, hormones, growth factors, anti-oxidants or other factors may be revealed that could advance our knowledge of the aging process. Or maybe removal of harmful factors from the old blood is the key to longevity?

Let us know what proof is needed to bolster the claim that young blood is benefiicial?

1 Like

@anttipe, @sully, @Wei, what are your thoughts on this?

@Avik, @joannabensz, have you heard about this? What is your opinion?

There are more than a few researchers studying circulating molecules and cells linked to aging ( ).
Cancer, Cardiovascular disease, and Alzheimer’s account for over half of “All Cause Mortality” in the developed world. These diseases have readily identifiable circulating biomarkers–targets for treatment, removal, or supplementation. Addition or removal of circulating factors seems like a viable treatment. But the approach needs to be specific and scientifically justified with clinical trials. Just infusing blood from young people into old people seems like an awkward first attempt.

@NikolaiKirienko, @LifespanKeith, @JoshuaN1993, what do you think about this?

This is a wild guess— but my hunch is that it’s a combination of factors one would expect to find in optimally healthy blood, vs micronutrient depleted blood: more oxygen saturated HgB, higher Crit, B12, Iron, etc. Take the supplements IV and complete 20 consecutive hyperbaric dives, and I’d wager anyone’s blood could be mistaken for young blood, and they’d feel as much improvement, with less risk for the same price.

From Bloomberg:

Click here to read the rest.